Peptide Library

Human study PLS-00070

The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease.

Cross-sectional study · 234 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease.primary · European review for medical and pharmacological sciences · 2023-09-01 · PMID 37750635 · DOI

Design and participants

Design
Cross-sectional study
Population
Adults with metabolic dysfunction-associated fatty liver disease (MAFLD) diagnosed by liver ultrasound (n=150, 57 male, median age 41.0) and healthy controls (n=84, 34 male, median age 36.0).
Conditions
Metabolic dysfunction-associated fatty liver disease, Metabolic syndrome, Liver fibrosis
Setting
Single-center
Planned enrollment (registry)
Not reported
Enrolled
234
Randomized
Not reported
Completed follow-up
Not reported
Funding
Not stated
Authors’ conflicts
Not stated

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound was administered.

    The authors concluded (paraphrased): People with MetS and MAFLD tend to have lower circulating MOTS-c. These lower levels correlate inversely with MetS components and with noninvasive fibrosis scores.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: MOTS-c was only measured as an endogenous biomarker. It was never administered, so the study gives no information on the effects of MOTS-c as a treatment.
    • confounding: Cross-sectional comparison of groups with differing age and sex distributions. The abstract reports no adjustment for confounders.
    • other: The cross-sectional design cannot establish whether low MOTS-c causes or results from metabolic disease.
    • abstract only: Only the abstract is available. Methods, adjustments and effect sizes are not reported in the record.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 37750635, abstract (Patients and methods, sentence 1; Results, sentences 1 and 3) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 37750635, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 37750635, abstract (Patients and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 37750635, abstract (Patients and methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 37750635, abstract (Patients and methods, sentences 2-3) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 37750635, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 37750635, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 37750635, abstract (Results, sentences 2-4) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).